MedTrace Logo

Melatonin in Adults With SMS

NCT03492970 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-04-22

No results posted yet for this study

Summary

Sleep-Wake and behavioral disorders in Smith Magenis Syndrome (SMS) are strongly linked to an inversion of the nychtemeral secretion of melatonin. This inversion have been described in children with SMS. However its evolution during adulthood remains unknown. The aim of this study is to assess 24hours melatonin levels in 10 adults with SMS in order to optimize medication in adults with SMS

Conditions

  • Smith Magenis Syndrome

Interventions

BIOLOGICAL

Hourly dosing of the nychtemeral secretion of melatonin

Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • Hôpital le Vinatier

    lead OTHER

Principal Investigators

  • POISSON ALICE, PH · CH LE VINATIER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2019-01-30
Completion
2019-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492970 on ClinicalTrials.gov